A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy
Jason B. Luoma, Christina Chwyl, Geoff J. Bathje, Alan K. Davis, Rafael Lancelotta
Journal of Psychoactive Drugs June 12, 2020 DOI: 10.1080/02791072.2020.1769878 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Randomized Placebo-controlled Peer reviewed |
|---|---|
| Interventions | Psilocybin LSD ayahuasca MDMA |
| Topics | Anxiety Psilocybin Psychedelic-assisted therapy |
| Keywords | Placebo Hallucinogen Clinical trial Randomized controlled trial Clinical psychology |
| Citations | 206 |
| Key findings | Psychedelic-assisted therapy shows a large effect size (Hedges g = 1.21) compared to placebo across four mental health conditions. |
Abstract
After a two-decade hiatus in which research on psychedelics was essentially halted, placebo-controlled clinical trials of psychedelic-assisted therapy for mental health conditions have begun to be published. We identified nine randomized, placebo-controlled clinical trials of psychedelic-assisted therapy published since 1994. Studies examined psilocybin, LSD (lysergic acid diethylamide), ayahuasca (which contains a combination of N,N-dimethyltryptamine and harmala monoamine oxidase inhibitor alkaloids), and MDMA (3,4-methylenedioxymethamphetamine). We compared the standardized mean difference between the experimental and placebo control group at the primary endpoint. Results indicated a significant mean between-groups effect size of 1.21 (Hedges g), which is larger than the typical effect size found in trials of psychopharmacological or psychotherapy interventions. For the three studies that maintained a placebo control through a follow-up assessment, effects were generally maintained at follow-up. Overall, analyses support the efficacy of psychedelic-assisted therapy across four mental health conditions - post-traumatic stress disorder, anxiety/depression associated with a life-threatening illness, unipolar depression, and social anxiety among autistic adults. While study quality was high, we identify several areas for improvement regarding the conduct and reporting of trials. Larger trials with more diverse samples are needed to examine possible moderators and mediators of effects, and to establish whether effects are maintained over time.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
Across nine randomized placebo-controlled trials, psychedelic-assisted therapy showed a significant mean between-groups effect size of Hedges g = 1.21, with effects generally maintained at follow-up.
Synthesized
Comparable studies
Other systematic reviews and meta-analyses on psilocybin and psychedelic-assisted therapy, most cited first.